Faculty Profiles - HONDA, Takashi

Papers - HONDA, Takashi

Division display 21 - 40 of about 256 ／ All the affair displays >>

Impact of BMI and Body Composition on First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma Reviewed International journal

Yamamoto T, Ito T, Mizuno K, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H.

Anticancer Res Vol. 44 ( 9 ) page： 4101 - 4111 2024.7

Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study Reviewed International coauthorship International journal

Ji F, Tran S, Ogawa E, Huang CF, Suzuki T, Wong YJ, Toyoda H, Jun DW, Li L, Uojima H, Nozaki A, Chuma M, Tseng CH, Hsu YC, Ishigami M, Honda T, Atsukawa M, Haga H, Enomoto M, Trinh H, Preda CM, Vutien P, Landis C, Lee DH, Watanabe T, Takahashi H, Abe H, Asai A, Eguchi Y, Li J, Wang X, Li J, Liu J, Liang J, Lam CP, Huang R, Ye Q, Pan H, Zhang J, Cai D, Wang Q, Huang DQ, Wong G, Wong VW, Li J, Do S, Furusyo N, Nakamuta M, Nomura H, Kajiwara E, Yoon EL, Ahn SB, Azuma K, Dohmen K, An J, Song DS, Cho HC, Kawano A, Koyanagi T, Ooho A, Satoh T, Takahashi K, Yeh ML, Tsai PC, Yasuda S, Zhao Y, Liu Y, Okubo T, Itokawa N, Jun MJ, Ishikawa T, Takaguchi K, Senoh T, Zhang M, Zhao C, Alecu RI, Xuan Tay W, Devan P, Liu JK, Kozuka R, Vargas-Accarino E, Do AT, Maeda M, Chuang WL, Huang JF, Dai CY, Cheung R, Buti M, Niu J, Xie W, Ren H, Lim SG, Wu C, Yuen MF, Shang J, Zhu Q, Ueno Y, Tanaka Y, Hayashi J, Yu ML, Nguyen MH.

J Clin Transl Hepatol Vol. 28 ( 7 ) page： 646 - 658 2024.7

Predicting Early Rebleeding and Mortality After Endoscopic Hemostasis of Esophagogastric Varices: Diagnostic Performance of Aspartate Aminotransferase-to-Platelet Ratio Index and Model for End-Stage Liver Disease-Na Score Reviewed International journal

Yokoyama S, Honda T, Ishizu Y, Imai N, Ito T, Yamamoto K, Mizuno K, Nakamura N, Kawashima H

J Hepatobiliary Pancreat Sci. 2024.7

Clinical Outcomes of Use of the Porous Glass Membrane Pumping Emulsification Device During Transarterial Chemoembolization for Hepatocellular Carcinoma Reviewed International journal

Mizuno F, Imai N, Mizuno K, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Kawashima H.

Anticancer Res. Vol. 44 ( 7 ) page： 3185 - 3191 2024.7

Risk factors for decreased bone mineral density in patients with metabolic dysfunction-associated steatotic liver disease: a cross-sectional study at a health examination center Reviewed International journal

Yokoyama S, Honda T, Ishizu Y, Imai N, Ito T, Yamamoto K, Mizuno K, Kojima T, Kariya N, Nakamura N, Kawashima H

Clinical Nutrition Vol. 43 ( 6 ) page： 1425 - 1432 2024.6

Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team Reviewed International journal

Ito T, Mizuno K, Yamamoto T, Yasuda T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Hama M, Kataoka T, Shimokata T, Ando Y, Kawashima H.

Hepatol Res. 2024.4

Intestinal Microbiome Associated with Efficacy of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma Reviewed International journal

Inukai Y, Yamamoto K, Honda T*, Yokoyama S, Ito T, Ishigami M, Kawashima H

Cancers Vol. 26 ( 16 ) page： 1675 2024.4

Identification of the microbiome associated with prognosis in patients with chronic liver disease Reviewed International journal

Yamamoto K, Honda T, Inukai Y, Yokoyama S, Ito T, Imai N, Ishizu Y, Nakamura M, Kawashima H

Microorganisms Vol. 12 ( 3 ) page： 610 2024.3

Characteristics of microbiomes of the saliva, duodenal bulb, and descending portion of superficial nonampullary duodenal epithelial tumors Reviewed International journal

Shibata H, Yamamoto K, Hirose T, Furune S, Kakushima N, Furukawa K, Nakamura M, Honda T*, Fujishiro M, Kawashima H.

Dig Liver Dis 2024.2

Analysis of Neuropeptides in the Intestinal Mucus of Patients with Ulcerative Colitis Using RNA Sequencing Reviewed International journal

Nakamura M, Murate K, Maeda K, Yamamura T, Sawada T, Ishikawa E, Furukawa K, Hirose T, Uetsuki K, Iida T, Mizutani Y, Yamao K, Ishizu Y, Ishikawa T, Honda T, Kawashima H

Digestion Vol. 105 ( 5 ) page： 400 - 410 2024

Long-term monitoring and clinical implications of small bowel capsule endoscopy in patients with Crohn's disease with small bowel lesions: A Retrospective Analysis Reviewed International journal

Nakamura M, Yamamura T, Maeda K, Sawada T, Ishikawa E, Murate K, Furukawa K, Hirose T, Uetsuki K, Iida T, Mizutani Y, Yamao K, Ishizu Y, Ishikawa T, Honda T, Kawashima H

Digestion Vol. 105 ( 5 ) page： 380 - 388 2024

*Effects of 1‐kestose on microbiome changes caused by vonoprazan: a randomized, double‐blind, placebo‐controlled pilot study Reviewed International journal

Furune S, Suzuki T, Honda T*, Yamamoto K, Furukawa K, Nakamura M, Ishigami M, Kinoshita F, Kadota Y, Tochio T, Shimomura Y, Hirooka Y, Fujishiro M, Hirroka Y, Kawashima H

J Gastroenterol Hepatol. 2023.12

Monoclonal Antibody Against Mature Interleukin-18 Ameliorates Colitis in Mice and Improves Epithelial Barrier Function Reviewed International journal

Ikegami S, Maeda K, Urano T, Mu J, Nakamura M, Yamamura T, Sawada T, Ishikawa E, Yamamoto K, Muto H, Oishi A, Iida T, Mizutani Y, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Honda T, Ishigami M, Kawashima H.

Inflamm Bowel Dis 2023.12

*Impact of elobixibat on liver tumors, microbiome, and bile acid levels in a mouse model of nonalcoholic steatohepatitis. Reviewed International journal

Sugiyama Y, Yamamoto K, Honda T*, Kato A, Muto H, Yokoyama S, Ito T, Imai N, Ishizu Y, Nakamura M, Asano T, Enomoto A, Zaitsu K, Ishigami M, Fujishiro M, Kawashima H

Hepatology international Vol. 17 ( 6 ) page： 1378 - 1392 2023.12

A new criterion including the aspartate aminotransferase-to-platelet ratio index and liver and spleen stiffness to rule out varices needing treatment in children with biliary atresia: Modification of the Baveno VII criteria. Reviewed International journal

Hepatology research : the official journal of the Japan Society of Hepatology 2023.10

Clinical course and prognosis of patients with hepatocellular carcinoma and haemophilia. Reviewed International journal

European journal of gastroenterology & hepatology Vol. 35 ( 10 ) page： 1211 - 1215 2023.10

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis. Reviewed International journal

Inflammatory intestinal diseases Vol. 8 ( 2 ) page： 60 - 68 2023.10

Clinical characteristics of Dieulafoy’s Lesion in the Small Bowel Diagnosed and Treated by Double-Balloon Endoscopy Reviewed International journal

Nakamura M, Yamamura T, Maeda K, Sawada T, Ishikawa E, Furukawa K, Iida T, Mizutani Y, Yamao K, Ishikawa T, Honda T, Ishigami M, Kawashima H.

BMC Gastroenterol. Vol. 23 ( 1 ) page： 290 2023.8

Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients-authors' reply. Reviewed International journal

Alimentary pharmacology & therapeutics Vol. 57 ( 11 ) page： 1351 - 1352 2023.6

Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis. Reviewed International journal

Takafumi Yamamoto, Kazuyuki Mizuno, Takanori Ito, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Takuya Ishikawa, Akira Kanamori, Satoshi Yasuda, Hidenori Toyoda, Kenji Yokota, Tetsunari Hase, Naoki Nishio, Osamu Maeda, Makoto Ishii, Michihiko Sone, Yuichi Ando, Masashi Akiyama, Masatoshi Ishigami, Hiroki Kawashima

Investigational new drugs Vol. 41 ( 3 ) page： 512 - 521 2023.6

Language：English Publishing type：Research paper (scientific journal)

Immune-related sclerosing cholangitis (irSC) is relatively rare and its clinical characteristics are not well known. In this study, we aimed to summarize the clinical features of irSC. Clinical data were collected retrospectively from 1,393 patients with advanced malignancy treated with immune-checkpoint inhibitors (ICIs) between August 2014 and October 2021. We analyzed patients with immune-related adverse events of liver injury (liver-irAEs) and compared irSC and non-irSC groups. Sixty-seven patients (4.8%) had a liver-irAE (≥ grade 3) during the follow-up period (median, 262 days). Among these, irSC was observed in eight patients (11.9%). All patients in the irSC group were treated with anti-PD-1/PD-L1 antibodies. Compared with the non-irSC group, the irSC group showed mainly non-hepatocellular liver injury (87.5 % vs 50.8 %, P = 0.065), and had elevated serum inflammatory markers (e.g., CRP and NLR) and biliary enzymes (e.g., GGTP and ALP) at the onset of liver-irAEs. Furthermore, most patients with irSC had abdominal pain. In the non-irSC group, the liver injury of 23 patients improved only with the discontinuation of ICIs, and 22 patients improved with medication including prednisolone (PSL). Conversely, almost all patients (n=7) in the irSC group were treated with PSL, but only two patients experienced an improvement in liver injury. We found that irSC is characterized by a non-hepatocellular type of liver injury with abdominal pain and a high inflammatory response and is refractory to treatment. Further examination by imaging is recommended to detect intractable irSC in cases with these characteristics.

DOI： 10.1007/s10637-023-01366-3

Scopus

PubMed

　 PREV - NEXT 　

<HONDA, Takashi>

Papers - HONDA, Takashi